Q3-osavuosiraportti
6 päivää sittenTarjoustasot
Määrä
Osto
1
Myynti
Määrä
1 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,04VWAP
Alin
1,95VaihtoMäärä
1,4 1 228 550
VWAP
Ylin
2,04Alin
1,95VaihtoMäärä
1,4 1 228 550
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Vuosiraportti | 25.3. |
Datan lähde: Morningstar
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3.10.New sales director has been hired - Justin Bourne (great name) - he has 16 years of experience in the industry and seems extremely competent - they are looking good - the next 3-6 months will be a bird or fish 📈📉 🤞- ·19.9.Any lucky knights here? - I bought in at 3.94 🫣·21.9.Cool! - I hope their commercialization bears fruit here in the next 3-6 months with good initial sales figures and partnerships… I assume that the hospitals that have been involved in trials for FDA approval also intend to buy the product and if they also get going in other parts of the world, then hopefully we will hit + 8-12$ within the next 6-12 months. These are just assumptions and not a buy recommendation. Do your own research before buying/selling a stock.
9.9.9.9.While I would question the foundation for significant gains this week, being positively confident about the coming months is far from unreasonable. The FDA clearance was without a doubt reasonably priced in, contrary to what many expected. While it provided momentum, the execution of upcoming catalysts will be much more vital. Being a breakout biotech company it’s impossible to avoid uncertainty. Especially regarding development of sales, potential market capitalization and so on. Being confident in FDA approval, MBOT has been focused on preparing for market. They have been laying solid groundwork for their switch from research and engineering over to sales and marketing. These past months this has been the top priority. Already ahead of FDA approval MBOT put together a solid sales team, consisting of competent, experienced industry people. MBOT does also have many strong preexisting industry relationships, and due to this and an innovative and cost effective product, a potential buyout and possible partnerships could be in the near future. When it comes to upcoming catalysts, such as conventions and presentations, if product has competition it is customary to stay silent and let the numbers speak. Going down this road would probably not lead to much price action until Q4 earnings. However, why not make statements with the sole objective of investor confidence when you can back it up? This course of action seems obvious for a company with the ability to do so. To be upfront about projections could absolutely make things interesting short term, however MBOT is not a short term play. It’s most definitely long term. Despite recently receiving more media attention, MBOT still seems to be flying under the radar. While trading volume has picked up and the stock is in an upwards trend, few retail investors have even heard of it. As of now MBOT has a 200 million dollar market cap with a vastly superior product compared to all their competitors. Their Liberty remote controled endovascular robot has a 100% doctor approval rating while limiting lead exposure by 92% during a procedure. Endovascular robots are a 30 billion dollar industry. It’s not unrealistic to capture 2% of the market share in a year, being optimistic. Right now there is little reason to expect any considerable setbacks with the launch of Liberty. Cash on hand is no concern, due to capital gained issuing warrants. Though this has diluted the stock, the result is cash reserves lasting them 16 quarters. It is rare to find a company with a downside this small. Especially in biotech. Everything with this company seems like it’s heading in one direction. All things considering, the risk is minimal. I would claim the risk is at an equal level to stocks not in the biotech sector. It’s not often you can say with confidence that nothing can go wrong… and I’m not doing that. Cuz I have no idea what I’m yappin about this is me laughing at u cuz u read all that: 🫵😂 (u stoopid) I been browsing reddit, found this stock, put all my schmoney in this robot thing idk. Thats wassup tho… Now Im just writing stuff cuz Im bored and cant sleep. Fr tho, im lowkey pretty sure what im sayin is correct but like feel free to fact check and shii. Anyway, bought this at like 2,8$ and then I went all in at 3,8$. Hope that was smart, probably wasn’t but I really have no clue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
6 päivää sittenUutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.10.New sales director has been hired - Justin Bourne (great name) - he has 16 years of experience in the industry and seems extremely competent - they are looking good - the next 3-6 months will be a bird or fish 📈📉 🤞
- ·19.9.Any lucky knights here? - I bought in at 3.94 🫣·21.9.Cool! - I hope their commercialization bears fruit here in the next 3-6 months with good initial sales figures and partnerships… I assume that the hospitals that have been involved in trials for FDA approval also intend to buy the product and if they also get going in other parts of the world, then hopefully we will hit + 8-12$ within the next 6-12 months. These are just assumptions and not a buy recommendation. Do your own research before buying/selling a stock.
- 9.9.9.9.While I would question the foundation for significant gains this week, being positively confident about the coming months is far from unreasonable. The FDA clearance was without a doubt reasonably priced in, contrary to what many expected. While it provided momentum, the execution of upcoming catalysts will be much more vital. Being a breakout biotech company it’s impossible to avoid uncertainty. Especially regarding development of sales, potential market capitalization and so on. Being confident in FDA approval, MBOT has been focused on preparing for market. They have been laying solid groundwork for their switch from research and engineering over to sales and marketing. These past months this has been the top priority. Already ahead of FDA approval MBOT put together a solid sales team, consisting of competent, experienced industry people. MBOT does also have many strong preexisting industry relationships, and due to this and an innovative and cost effective product, a potential buyout and possible partnerships could be in the near future. When it comes to upcoming catalysts, such as conventions and presentations, if product has competition it is customary to stay silent and let the numbers speak. Going down this road would probably not lead to much price action until Q4 earnings. However, why not make statements with the sole objective of investor confidence when you can back it up? This course of action seems obvious for a company with the ability to do so. To be upfront about projections could absolutely make things interesting short term, however MBOT is not a short term play. It’s most definitely long term. Despite recently receiving more media attention, MBOT still seems to be flying under the radar. While trading volume has picked up and the stock is in an upwards trend, few retail investors have even heard of it. As of now MBOT has a 200 million dollar market cap with a vastly superior product compared to all their competitors. Their Liberty remote controled endovascular robot has a 100% doctor approval rating while limiting lead exposure by 92% during a procedure. Endovascular robots are a 30 billion dollar industry. It’s not unrealistic to capture 2% of the market share in a year, being optimistic. Right now there is little reason to expect any considerable setbacks with the launch of Liberty. Cash on hand is no concern, due to capital gained issuing warrants. Though this has diluted the stock, the result is cash reserves lasting them 16 quarters. It is rare to find a company with a downside this small. Especially in biotech. Everything with this company seems like it’s heading in one direction. All things considering, the risk is minimal. I would claim the risk is at an equal level to stocks not in the biotech sector. It’s not often you can say with confidence that nothing can go wrong… and I’m not doing that. Cuz I have no idea what I’m yappin about this is me laughing at u cuz u read all that: 🫵😂 (u stoopid) I been browsing reddit, found this stock, put all my schmoney in this robot thing idk. Thats wassup tho… Now Im just writing stuff cuz Im bored and cant sleep. Fr tho, im lowkey pretty sure what im sayin is correct but like feel free to fact check and shii. Anyway, bought this at like 2,8$ and then I went all in at 3,8$. Hope that was smart, probably wasn’t but I really have no clue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1
Myynti
Määrä
1 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,04VWAP
Alin
1,95VaihtoMäärä
1,4 1 228 550
VWAP
Ylin
2,04Alin
1,95VaihtoMäärä
1,4 1 228 550
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Vuosiraportti | 25.3. |
Datan lähde: Morningstar
Q3-osavuosiraportti
6 päivää sittenUutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 12.11. | |
| 2025 Q2-osavuosiraportti | 12.8. | |
| 2025 Yhtiökokous | 10.6. | |
| 2025 Q1-osavuosiraportti | 14.5. | |
| 2024 Vuosiraportti | 25.3. |
Datan lähde: Morningstar
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.10.New sales director has been hired - Justin Bourne (great name) - he has 16 years of experience in the industry and seems extremely competent - they are looking good - the next 3-6 months will be a bird or fish 📈📉 🤞
- ·19.9.Any lucky knights here? - I bought in at 3.94 🫣·21.9.Cool! - I hope their commercialization bears fruit here in the next 3-6 months with good initial sales figures and partnerships… I assume that the hospitals that have been involved in trials for FDA approval also intend to buy the product and if they also get going in other parts of the world, then hopefully we will hit + 8-12$ within the next 6-12 months. These are just assumptions and not a buy recommendation. Do your own research before buying/selling a stock.
- 9.9.9.9.While I would question the foundation for significant gains this week, being positively confident about the coming months is far from unreasonable. The FDA clearance was without a doubt reasonably priced in, contrary to what many expected. While it provided momentum, the execution of upcoming catalysts will be much more vital. Being a breakout biotech company it’s impossible to avoid uncertainty. Especially regarding development of sales, potential market capitalization and so on. Being confident in FDA approval, MBOT has been focused on preparing for market. They have been laying solid groundwork for their switch from research and engineering over to sales and marketing. These past months this has been the top priority. Already ahead of FDA approval MBOT put together a solid sales team, consisting of competent, experienced industry people. MBOT does also have many strong preexisting industry relationships, and due to this and an innovative and cost effective product, a potential buyout and possible partnerships could be in the near future. When it comes to upcoming catalysts, such as conventions and presentations, if product has competition it is customary to stay silent and let the numbers speak. Going down this road would probably not lead to much price action until Q4 earnings. However, why not make statements with the sole objective of investor confidence when you can back it up? This course of action seems obvious for a company with the ability to do so. To be upfront about projections could absolutely make things interesting short term, however MBOT is not a short term play. It’s most definitely long term. Despite recently receiving more media attention, MBOT still seems to be flying under the radar. While trading volume has picked up and the stock is in an upwards trend, few retail investors have even heard of it. As of now MBOT has a 200 million dollar market cap with a vastly superior product compared to all their competitors. Their Liberty remote controled endovascular robot has a 100% doctor approval rating while limiting lead exposure by 92% during a procedure. Endovascular robots are a 30 billion dollar industry. It’s not unrealistic to capture 2% of the market share in a year, being optimistic. Right now there is little reason to expect any considerable setbacks with the launch of Liberty. Cash on hand is no concern, due to capital gained issuing warrants. Though this has diluted the stock, the result is cash reserves lasting them 16 quarters. It is rare to find a company with a downside this small. Especially in biotech. Everything with this company seems like it’s heading in one direction. All things considering, the risk is minimal. I would claim the risk is at an equal level to stocks not in the biotech sector. It’s not often you can say with confidence that nothing can go wrong… and I’m not doing that. Cuz I have no idea what I’m yappin about this is me laughing at u cuz u read all that: 🫵😂 (u stoopid) I been browsing reddit, found this stock, put all my schmoney in this robot thing idk. Thats wassup tho… Now Im just writing stuff cuz Im bored and cant sleep. Fr tho, im lowkey pretty sure what im sayin is correct but like feel free to fact check and shii. Anyway, bought this at like 2,8$ and then I went all in at 3,8$. Hope that was smart, probably wasn’t but I really have no clue.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
1
Myynti
Määrä
1 641
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
2,04VWAP
Alin
1,95VaihtoMäärä
1,4 1 228 550
VWAP
Ylin
2,04Alin
1,95VaihtoMäärä
1,4 1 228 550
Välittäjätilasto
Dataa ei löytynyt